Work

Zebra fish as a model for translational neurobiology: Implications for drug discovery and development

Year: 2017
Type: dissertation
Abstract: Diseases which affect the central nervous system present a huge burden to sufferers and caregivers.In tandem with longevity, prevalences of age-related neurodegenerative diseases are increasing.However, despite the evident necessity for pharmaceutical interventions, there has been a distinct lack of drug development to combat these disorders.This is largely attributed to high financial costs of using rodent models.Thus the validation of a more cost-effective in vivo system would facilitate pharmaceutical screening.The work presented in this thesis addresses this issue by assessing the utility of zebrafish in two costly areas of translational neurobiology -lead identification and safety pharmacology.An aversive classical conditioning assay was developed and automated as a behavioural screening method.This robust assay allows fast assessment of cognition and cognitive decline.The effect of neurotoxin treatment on aversive learning was then assessed using this assay, demonstrating its efficacy as a screening tool for neurodegeneration research.Subsequently, a transgenic zebrafish line -expressing a mutated form of the Alzheimer's-associated human amyloid precursor protein -was assessed, demonstrating an age-related cognitive impairment.Additionally new genetic zebrafish lines were generated, which over-express genes (both endogenous and transgenic) related to Alzheimer's-like pathologies.Whilst these were not assessed within this thesis, they present promising tools for possible future investigations.Regarding safety pharmacology, regulatory bodies require all CNS-penetrant drugs be assessed for abuse potential.Zebrafish display reward responses to several common drugs of abuse (e.g.amphetamine, cocaine, morphine).Thus, the latter sections of this thesis evaluated the utility of zebrafish for assessing human abuse potential.A CPP paradigm was utilised to test a range of drugs, with the sensitivity and specificity of zebrafish compared to previous reports using rodent.Additionally, the development of a zebrafish drug discrimination assay was attempted.However the paradigms utilised failed to develop an efficacious assay.LIST OF FIGURES 4.1 Aluminium exposure induces mitochondrial dysfunction and ER stress.A simplistic pathway of Al-induced cellular dysfunction in relation to molecular dysregulation.Al disrupts Na + /Ca 2+ exchanger functioning, resulting in an increase in cytoplasmic, and subsequently mitochondrial Ca 2+ .This leads to the secretion of cytochrome c, which binds APAF-1 to initiate apoptotic caspase signalling.Additionally, the mitochondrial dysfunction leads to increased generation of reactive oxygen species (ROS), which causes the translocation of NF-κB (resulting in inflammation) and GADD153 (which inhibits the anti-apoptotic action of BCL-2).Al also down-regulates GRP78 (resulting in disregulated UPR signalling and increased activity of caspase 7 and caspase 9) and increases apoptotic signalling via upregulation of caspase 12. (Yellow text on red background, neurodegenerative effect; white text on blue background, neuroprotective effect; ˆrg, up-regulation; ∨ rg, down-regulation; yellow 'lightning symbol', dissociation of bound proteins.) . . . . . . . . . . . . . . . . . . . . .101 4.2 Effects of aluminium on the phosphorylation of tau.Tau is phosphorylated by GSK3β (a mechanism instigated by Aβ), and dephosphorylated by PP2A.Aluminium has been shown to decrease PP2A activity, suggesting that its facilitation of tau phosphorylation results from inhibition of dephosphorylation.(Yellow text on red background, neurodegenerative effect; white text on blue background, neuroprotective effect) . . . . . . . . . . . . . . . . . . . . . . . . . .105 4.3 APP metabolism by secretase enzymes.In relation to ADpathologies, APP is generally regarded as being processed by one of two pathways.In the 'amyloidogenic pathway', β-secretases (e.g.BACE1) cleave at a specific site (β site) of the protein, releasing a soluble fragment (s-APPβ) from the N-teminal.The remaining transmembrane C-terminal fragment is subsequently cleaved by γ-secretase in one of several neighbouring sites, releasing an Aβ peptide between 39-42aa long.In the 'non-amyloidogenic pathway', α-secretases (ADAM genes) cleave at a specific site (α site) of the APP protein, releasing a longer soluble fragment (s-APPα) from the N-terminal.As the α site is located within the region of the Aβ peptide, this peptide is not released by the subsequent γ-secretase cleavage of the transmembrane C-terminal fragment.(Image from Zhang and Saunders 2009). . . . . . . . . . . . . . . . . . . . . . . . .106 4.4 Aluminium dysregulates AD-related genes and disrupts neuroprotective signalling.Aluminium exposure increases the protein expression levels of both APP and BACE1.It has also been demonstrated to affect the secondary structure of PIN1, converting α-helices into β-sheets.This, in turn, disrupts the neuroprotective consequences of PIN1 signalling (i.e.inhibition of Aβ aggregation and dephosphorylation of tau).(Yellow text on red background, neurodegenerative effect; white text on blue background, neuroprotective effect; ˆrg, up-regulation; 2 o α > β, protein secondary structure change from α helix to β sheet) . . . . . . . . . .
Author: Ari Sudwarts
Language: English
Subfield: Cell Biology
Open Access status: green
OpenAlex ID: W2768083543
Cites: 882
Cited by: 3
Related to: 10